Stockscreener 앱 받기
4.43
3.26%
0.14
전일 마감가:
$4.29
열려 있는:
$4.25
하루 거래량:
14,181
Relative Volume:
0.10
시가총액:
$68.61M
수익:
-
순이익/손실:
-
주가수익비율:
-6.2465
EPS:
-0.7092
순현금흐름:
-
1주 성능:
+2.31%
1개월 성능:
-9.22%
6개월 성능:
+41.31%
1년 성능:
+244.75%
1일 변동 폭
$4.15
$4.47
1주일 범위
$4.12
$4.66
52주 변동 폭
$1.001
$7.00
알테리티 테라퓨틱스 Stock (ATHE) Company Profile
ATHE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
4.47 | 77.76M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.75 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.73 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.86 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.40 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.15 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
알테리티 테라퓨틱스 Stock (ATHE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-03 | 다운그레이드 | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | 개시 | Maxim Group | Buy |
알테리티 테라퓨틱스 주식(ATHE)의 최신 뉴스
Alterity Therapeutics stock rises after positive MSA trial data presented at conference - Investing.com
Alterity Therapeutics (NASDAQ:ATHE) Shares Down 0.5% – What’s Next? - Defense World
Alterity Therapeutics presents ATH434-201 Phase 2 data - TipRanks
ASX recovers to shed just 0.13pc as healthcare and gold drags - Geelong Advertiser
Alterity Therapeutics raises A$20M in strategic placement - MSN
ATHE: A Tale of Ups & Downs – 63.16% gain in 6 Months, 42.35% in 30 Days - investchronicle.com
SMCI’s Market Flip-Flop: Exploring the Volatility of 2025 Performance - investchronicle.com
Alterity CEO to provide corporate update on ATH434 development - Investing.com
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Alterity Therapeutics highlighted at MSA Congress By Investing.com - Investing.com India
Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity shares new phase 2 data on MSA treatment - Investing.com
Alterity Therapeutics announces regulatory notice - Investing.com
Alterity Therapeutics completes placement - Investing.com
Alterity Therapeutics announces compliance notice - Investing.com
Alterity secures funding to advance MSA drug development - Investing.com
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com
Alterity Therapeutics announces securities notice - Investing.com
Alterity Therapeutics reports quarterly activities - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Most active stocks: US stocks with the highest trading volume today - Yahoo
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
symbol__ Stock Quote Price and Forecast - CNN
Biotech Stocks: Longevity Company Stocks - Investing.com
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
Trading Halts Explained - MarketBeat
Biggest Stock LosersToday’s Biggest Percentage Decliners - MarketBeat
Alterity Therapeutics LtdADR Shares Close the Week 40.3% HigherWeekly Wrap - Nasdaq
ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
ATH Stock Price and Chart — ASX:ATH - TradingView
Most Volatile Stocks, What Investors Need to Know - MarketBeat
A Full List of Australia ADRs - Investing.com Australia
How Investors Can Identify and Successfully Trade Gap-Down Stocks - MarketBeat
What Investors Need to Know to Beat the Market - MarketBeat
Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time - MarketBeat
알테리티 테라퓨틱스 (ATHE) 재무 분석
알테리티 테라퓨틱스 (ATHE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.21%
2.95%
자본화:
|
볼륨(24시간):